Last reviewed · How we verify
Multicentric Intracerebral Grafting in Huntington's Disease (MIG-HD)
The aim of this study is to assess the clinical benefit of intrastriatal grafting of human cells from the foetal ganglionic eminence in patients with Huntington's disease. The duration of the study will be 52 months. A first group of patients will be grafted at M13-14 (early G group) and a second group of patients will be grafted at M33-34 (late G group). The principal criterion is the comparison of the progression between M12 and M32 of the motor score (TMS) of the UHDRS between grafted patients (early G group) and not yet grafted patients (late G group). An additional evaluation will be performed to compare the progression in individual patients over the 52-month study period. We will thus be able to compare the pre and post-graft TMS progression for all patients.
Details
| Lead sponsor | Assistance Publique - Hôpitaux de Paris |
|---|---|
| Phase | Phase 2 |
| Status | COMPLETED |
| Enrolment | 54 |
| Start date | 2002-01 |
| Completion | 2013-12 |
Conditions
- Huntington Disease
Interventions
- graft intracerebral of foetal neurons
Primary outcomes
- Motor UHDRS rating scale, at randomization, 20 month after transplant — during de study
Countries
France